

Chan Kim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2289294/publications.pdf>

Version: 2024-02-01

52
papers

2,251
citations

304743

22
h-index

302126

39
g-index

53
all docs

53
docs citations

53
times ranked

3839
citing authors

#	ARTICLE	IF	CITATIONS
1	Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. <i>Experimental and Molecular Medicine</i> , 2020, 52, 1475-1485.	7.7	306
2	Normalization of Tumor Vessels by Tie2 Activation and Ang2 Inhibition Enhances Drug Delivery and Produces a Favorable Tumor Microenvironment. <i>Cancer Cell</i> , 2016, 30, 953-967.	16.8	259
3	STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade. <i>Journal of Clinical Investigation</i> , 2019, 129, 4350-4364.	8.2	178
4	Methylation-dependent regulation of HIF-1 α stability restricts retinal and tumour angiogenesis. <i>Nature Communications</i> , 2016, 7, 10347.	12.8	159
5	Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. <i>BMC Cancer</i> , 2016, 16, 434.	2.6	124
6	Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2021, 74, 350-359.	3.7	122
7	Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade. <i>Clinical Cancer Research</i> , 2019, 25, 1612-1623.	7.0	120
8	Differential Prognostic Implications of Gastric Signet Ring Cell Carcinoma. <i>Annals of Surgery</i> , 2017, 265, 946-953.	4.2	117
9	Vascular RhoJ Is an Effective and Selective Target for Tumor Angiogenesis and Vascular Disruption. <i>Cancer Cell</i> , 2014, 25, 102-117.	16.8	109
10	Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer. <i>Molecular Cancer</i> , 2011, 10, 36.	19.2	82
11	STING signaling is a potential immunotherapeutic target in colorectal cancer. <i>Journal of Cancer</i> , 2019, 10, 4932-4938.	2.5	51
12	STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer. , 2021, 9, e002195.		49
13	Bone alkaline phosphatase as a surrogate marker of bone metastasis in gastric cancer patients. <i>BMC Cancer</i> , 2016, 16, 385.	2.6	46
14	Peripheral Blood-Based Biomarkers for Immune Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9414.	4.1	46
15	Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascites. <i>Oncotarget</i> , 2016, 7, 8055-8066.	1.8	42
16	Clinical Value of Ezrin Expression in Primary Osteosarcoma. <i>Cancer Research and Treatment</i> , 2009, 41, 138.	3.0	39
17	Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with immune checkpoint inhibitor to suppress peritoneal carcinomatosis in colon cancer. , 2020, 8, e000857.		37
18	Combination Immunotherapy Using Oncolytic Virus for the Treatment of Advanced Solid Tumors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7743.	4.1	36

#	ARTICLE	IF	CITATIONS
19	PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer. <i>Oncotarget</i> , 2017, 8, 113494-113501.	1.8	34
20	Combination of Irreversible Electroporation and STING Agonist for Effective Cancer Immunotherapy. <i>Cancers</i> , 2020, 12, 3123.	3.7	33
21	Baicalein inhibits tumor progression by inhibiting tumor cell growth and tumor angiogenesis. <i>Oncology Reports</i> , 2017, 38, 3011-3018.	2.6	25
22	Docetaxel versus Paclitaxel Combined with 5-FU and Leucovorin in Advanced Gastric Cancer: Combined Analysis of Two Phase II Trials. <i>Cancer Research and Treatment</i> , 2009, 41, 196.	3.0	25
23	Novel Glycosylated VEGF Decoy Receptor Fusion Protein, VEGF-Grab, Efficiently Suppresses Tumor Angiogenesis and Progression. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 470-479.	4.1	24
24	Predictive Nomogram for Recurrence of Stage I Colorectal Cancer After Curative Resection. <i>Clinical Colorectal Cancer</i> , 2018, 17, e513-e518.	2.3	24
25	Combination Immunotherapies to Overcome Intrinsic Resistance to Checkpoint Blockade in Microsatellite Stable Colorectal Cancer. <i>Cancers</i> , 2021, 13, 4906.	3.7	18
26	Rho GTPase RhoJ is Associated with Gastric Cancer Progression and Metastasis. <i>Journal of Cancer</i> , 2016, 7, 1550-1556.	2.5	16
27	The clinical implications of FDG-PET/CT differ according to histology in advanced gastric cancer. <i>Gastric Cancer</i> , 2019, 22, 113-122.	5.3	16
28	Antitumor effects of IL-12 and GM-CSF co-expressed in an engineered oncolytic HSV-1. <i>Gene Therapy</i> , 2021, 28, 186-198.	4.5	16
29	Different subtypes of epithelioid sarcoma and their clinical implication: long-term multi-institutional experience with a rare sarcoma. <i>Apmis</i> , 2017, 125, 223-229.	2.0	15
30	High endothelial venule is a surrogate biomarker for T-cell inflamed tumor microenvironment and prognosis in gastric cancer. , 2021, 9, e003353.		14
31	The Clinicopathologic Features and Prognostic Impact of ALK Positivity in Patients with Resected Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 3938-3945.	1.5	13
32	Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab. <i>Oncotarget</i> , 2017, 8, 31169-31179.	1.8	13
33	The presence and size of intrahepatic tumors determine the therapeutic efficacy of nivolumab in advanced hepatocellular carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211132.	3.2	10
34	Clinical pattern and implication of PD-L1 expression in soft-tissue sarcoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 10565-10565.	1.6	6
35	Deep learning model enables the discovery of a novel immunotherapeutic agent regulating the kynurenine pathway. <i>Oncolimmunology</i> , 2021, 10, 2005280.	4.6	6
36	Targeting Actomyosin Contractility Suppresses Malignant Phenotypes of Acute Myeloid Leukemia Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3460.	4.1	5

#	ARTICLE	IF	CITATIONS
37	Prognostic model in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitors after platinum failure. <i>Current Problems in Cancer</i> , 2022, 46, 100848.	2.0	5
38	Abstract 1914: Orally available oncolytic reovirus, RC402, effectively promotes anti-cancer immunity and synergizes with immune checkpoint blockade in colon cancer. , 2021, , .		3
39	Emerging targeted therapies in advanced bladder cancer. <i>Translational Cancer Research</i> , 2017, 6, S666-S676.	1.0	3
40	Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer. <i>European Journal of Cancer</i> , 2019, 112, 20-28.	2.8	2
41	REACH-2: first biomarker-based anti-angiogenic therapy in patients with advanced hepatocellular carcinoma. <i>Chinese Clinical Oncology</i> , 2020, 9, 58-58.	1.2	1
42	Paraplegia following Epidural Analgesia. <i>Daehan Macwi'gwa Haghoeji</i> , 1988, 21, 389.	0.2	1
43	A Case of Unilateral Blindness Occuring During General Anesthesia for Neurosurgical Operation. <i>Daehan Macwi'gwa Haghoeji</i> , 1989, 22, 770.	0.2	1
44	A Clinieal Study of the Effect of Steroid Administered in Epidural Space for Back Pain and Sciatica. <i>Daehan Macwi'gwa Haghoeji</i> , 1984, 17, 121.	0.2	0
45	Transcutaneous Monitoring of PO2 and PCO2 during General Anesthesia in Adult Patient. <i>Daehan Macwi'gwa Haghoeji</i> , 1985, 18, 244.	0.2	0
46	Invasive and Non-invasive Blood Pressure Measurement during Anesthesia. <i>Daehan Macwi'gwa Haghoeji</i> , 1987, 20, 9.	0.2	0
47	The Incidence and Causes of Failed Spinal Anesthesia. <i>Daehan Macwi'gwa Haghoeji</i> , 1987, 20, 172.	0.2	0
48	Retrograde Tracheal Intubation through Cricothyroid Membrane. <i>Daehan Macwi'gwa Haghoeji</i> , 1989, 22, 934.	0.2	0
49	Clinical Experience of Anesthesia for Open Heart Surgery - 100 cases. <i>Daehan Macwi'gwa Haghoeji</i> , 1990, 23, 630.	0.2	0
50	Modeling post-progression survival in patients with HER2-positive metastatic gastric cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15020-e15020.	1.6	0
51	Prognostic impact of different FDG-PET uptake according to histology in advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4113-4113.	1.6	0
52	Novel Small Molecules Capable of Blocking mTRAS-Signaling Pathway. <i>Frontiers in Oncology</i> , 2021, 11, 768022.	2.8	0